Free Trial
NASDAQ:ANIP

ANI Pharmaceuticals Q3 2025 Earnings Report

ANI Pharmaceuticals logo
$94.24 -0.66 (-0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$94.24 0.00 (0.00%)
As of 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANI Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
$1.74
Beat/Miss
N/A
One Year Ago EPS
N/A

ANI Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ANI Pharmaceuticals Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Friday, November 7, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

ANI Pharmaceuticals Earnings Headlines

NEW LAW: Congress Approves Setup For Digital Dollar?
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor Green, it's a bill that contains "the entire setup, groundwork and infrastructure to move from cash to digital currency."tc pixel
See More ANI Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ANI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ANI Pharmaceuticals and other key companies, straight to your email.

About ANI Pharmaceuticals

ANI Pharmaceuticals (NASDAQ:ANIP) is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care. Alongside its proprietary generics business, ANI provides contract development and manufacturing organization (CDMO) services, leveraging its integrated in-house capabilities in sterile and nonsterile production, analytical testing and regulatory support to meet the needs of pharmaceutical partners.

Primarily serving markets in North America, ANI maintains multiple U.S. manufacturing facilities certified for complex sterile and nonsterile operations. The company collaborates with major distributors, retail pharmacies, hospitals and healthcare systems, and continues to invest in process optimization and quality systems to expand its product pipeline and support evolving patient needs.

View ANI Pharmaceuticals Profile

More Earnings Resources from MarketBeat